
[9] Pathogenic elevations of bile acid levels have been linked to variations in FGF19 levels (Vergnes et al., Cell Metabolism (2013) 17, 916-28). Reduction in the level of FGF19 may therefore be of benefit in promoting the synthesis of bile acid and thus in the treatment of hyperlipidemia.

[10] There is still a need for new FGFR4 inhibitors. In this regard, the compounds provided herein address the need.

BRIEF SUMMARY

[10a] In an aspect of the present disclosure, there is provided a compound of formula (I):



(I),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

---- is a single bond or a double bond;

X is CH or C;

L_1 is -CR'R"-, -O-, or -NR'"-, wherein R' and R" are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, or halo, and R'" is H, C_{1-6} alkyl, C_{1-6} haloalkyl, or acyl;

L_2 is a bond or $-CH_2-$;

A is a C_{6-14} arylene, 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene,

provided that when L_1 is $-CH_2-$ and L_2 is a bond, then A is 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene;

R^1, R^2, R^3, R^4, and R^5 are each independently H, halo, -OCD_3, -CN, $-NO_2$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^{11}R^{12}$,

or R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl;

m is 0, 1, or 2;

each R^7 is independently halo, -CN, $-NO_2$, C_{1-6} alkyl, $-CD_3$, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^aR^b$, wherein R^a and R^b are each independently H or C_{1-6} alkyl optionally substituted by $-NR^cR^d$, wherein R^c and R^d are each independently H or C_{1-6} alkyl;

R^8 is $–C(O)R^9$ or $–S(O)_2R^9$;

R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with C_{1-6} alkyl, halo, -CN, or $–C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl; and

R^{11}, R^{12}, and R^{13} are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{6-14} aryl, 5- to 10- membered heteroaryl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl;

provided that the compound is not a compound selected from the group consisting of:

N-(3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-pyrazol-4-yl)acrylamide,

N-(3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2,6-difluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2-fluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,


N-(5-(6-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide, and

N-(5-(6-(2-chloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

[10b] In another aspect of the present disclosure, there is provided a compound of formula (II):



(II),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

~~==== is a single bond or a double bond;~~

~~X is CH or C;~~

L_1 is -CR'R''-, -O-, or -NR'''-, wherein R' and R'' are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, or halo, and R''' is H, C_{1-6} alkyl, C_{1-6} haloalkyl, or acyl;

~~L_2 is a bond or -CH_2-;~~

A is a C_{6-14} arylene, 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene;R^1, R^2, R^3, R^4, and R^5 are each independently H, halo, -OCD_3, -CN, -NO_2, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, -OR^{13}, or -$NR^{11}R^{12}$,

or R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl;

m is 0, 1, or 2;


each R^7 is independently halo, -CN, -NO_2, C_{1-6} alkyl, -CD_3, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, -OR^{13}, or -NR^aR^b, wherein R^a and R^b are each independently H or C_{1-6} alkyl, wherein the C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, and -OR^{13} of R^7 and the C_{1-6} alkyl of R^a and R^b are each independently optionally substituted by -NR^cR^d, wherein R^c and R^d are each independently H or C_{1-6} alkyl;

R^8 is $–C(O)R^9$ or $–S(O)_2R^9$;


R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with C_{1-6} alkyl, halo, -CN, or $–C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl; and

R^{11}, R^{12}, and R^{13} are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{6-14} aryl, 5- to 10- membered heteroaryl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl.


[10c] In a further aspect of the present disclosure, there is provided a compound selected from the ~~compounds in Table 1,~~group consisting of




;




;




;




;




;




;




;




;




;




;




;



;




;




;


3d


O
HN
HN–N
F
O
N–N
F
O


;


O
HN
HN–N
F
D3C
O
N–N
H
D3C
O


;


O
HN
HN–N
F
O
N–N
F
O


;


O
HN
HN–N
F
O
N–N
F
O


;


O
HN
HN–N
F
O
N–NH
F
O


;


O
HN
HN–N
F
O
N–N
F
O

;



O
HN
HN–N
F
O
N–N
D3C
O

;



O
HN
HN–N
F
O
N–NH
O

;


3e


O
HN
HN
N
F
O
N
NH
O


;


O
HN
HN
N
F
O
N
N
O


;


O
O
F
H
N
N
O
H
N
N
N
O


;


O
F
O
F
H
N
N
HN
O
O


;


O
F
O
H
N
N
HN
O
O


;


O
F
O
F
H
N
N
HN
O
O

;



O
F
O
H
N
N
HN
O
O

;



O
F
O
F
H
N
N
HN
N
N
O

;


3f


O
F
O
F
H
N
N
HN
N
N
O


;


O
F
O
H
N
N
HN
N
N
O


;


O
HN–N
HN
O
O
F
O
F
N–N
O


;


O
HN–N
HN
O
O
F
O
F
N–N
O


;


O
HN–N
HN
O
O
F
F
N–N
O


;


O
HN
HN–N
O
F
(R)
N–N
F
O


;


O
HN
HN–N
F
(S)
N–N
O
F


;


O
HN
HN–N
F
(R)
N–N
O
F

;



O
HN
HN–N
F
(S)
N–N
O
F

;



O
HN
HN–N
F
(R)
N–NH
O
F

;


3g



;



; and



,

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

[10d] In another aspect of the present disclosure, there is provided a pharmaceutical composition comprising at least one compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier or excipient.


[10e] In a further aspect of the present disclosure, there is provided a kit comprising at least one compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing.

[10f] In another aspect of the present disclosure, there is provided a ~~method of treating a disease mediated by FGFR4 in an individual in need thereof, comprising administering to the individual a therapeutically effective amount~~ use of a compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for treating a disease mediated by FGFR4.

[10g] In a further aspect of the present disclosure, there is provided a ~~method of inhibiting FGFR4, comprising contacting FGFR4 with~~use of a compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for inhibiting FGFR4.

[10h] In another aspect of the present disclosure, there is provided ~~a use of~~ a compound disclosed herein, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, ~~in the manufacture of a medicament~~ for use in therapy.

[11] In one example, provided herein is a compound of formula (I):



(I),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein ----, X, L_1, L_2, A, m, R^1, R^2, R^3, R^4, R^5, R^7, and R^8 are as described herein.

[12] In another example, provided herein is a composition comprising a compound of formula (I) or any related formula, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing and a pharmaceutically acceptable carrier or excipient.

[13] In another example, provided herein is a kit comprising a compound of formula (I) or any related formula, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing.


[14] In another example, provided herein is a method of treating a disease mediated by FGFR4 in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of a compound of formula (I) or any related formula, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing. In some examples, the compound, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, is administered orally. In some examples, the disease is cancer. In some examples, the disease is liver cancer such as hepatocellular carcinoma,

~~3d~~

3j

CLAIMS

1. A compound of formula (I):



(I),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

---- is a single bond or a double bond;

X is CH or C;

L_1 is -CR'R"-, -O-, or -NR"'-, wherein R' and R" are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, or halo, and R"' is H, C_{1-6} alkyl, C_{1-6} haloalkyl, or acyl;

L_2 is a bond or $-CH_2-$;

A is a C_{6-14} arylene, 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene,

provided that when L_1 is $-CH_2-$ and L_2 is a bond, then A is 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene;

R^1, R^2, R^3, R^4, and R^5 are each independently H, halo, -OCD_3, -CN, $-NO_2$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^{11}R^{12}$,

or R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl;

m is 0, 1, or 2;

each R^7 is independently halo, -CN, $-NO_2$, C_{1-6} alkyl, -CD_3, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^aR^b$, wherein R^a and R^b are each independently H or C_{1-6} alkyl optionally substituted by $-NR^cR^d$, wherein R^c and R^d are each independently H or C_{1-6} alkyl;

R^8 is $–C(O)R^9$ or $–S(O)_2R^9$;

R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with C_{1-6} alkyl, halo, -CN, or $–C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl; and

R^{11}, R^{12}, and R^{13} are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{6-14} aryl, 5- to 10- membered heteroaryl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl;

provided that the compound is not a compound selected from the group consisting of:

N-(3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1H-pyrazol-4-yl)acrylamide,

N-(3-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2,6-dichloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2,6-difluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(2-fluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,


N-(5-(6-(2-chloro-6-fluoro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

N-(5-(6-(3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide, and

N-(5-(6-(2-chloro-3,5-dimethoxyphenyl)-4,5,6,7-tetrahydro-1H-indazol-3-yl)-1-methyl-1H-pyrazol-4-yl)acrylamide,

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

2. A compound of formula (II):



(II),

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein:

~~---- is a single bond or a double bond;~~

~~X is CH or C;~~

L_1 is -CR'R"-, -O-, or -NR'"-, wherein R' and R" are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, or halo, and R'" is H, C_{1-6} alkyl, C_{1-6} haloalkyl, or acyl;

~~L_2 is a bond or $-CH_2-$;~~

A is a C_{6-14} arylene, 5- to 10- membered heteroarylene, C_{3-8} cycloalkylene, or 3- to 10- membered heterocyclylene;R^1, R^2, R^3, R^4, and R^5 are each independently H, halo, -OCD_3, -CN, $-NO_2$, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^{11}R^{12}$,

or R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl;

m is 0, 1, or 2;


each R^7 is independently halo, -CN, $-NO_2$, C_{1-6} alkyl, -CD_3, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, $-OR^{13}$, or $-NR^aR^b$, wherein R^a and R^b are each independently H or C_{1-6} alkyl, wherein the C_{1-6} alkyl, C_{1-6} haloalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, and $-OR^{13}$ of R^7 and the C_{1-6} alkyl of R^a and R^b are each independently optionally substituted by $-NR^cR^d$, wherein R^c and R^d are each independently H or C_{1-6} alkyl;

R^8 is $–C(O)R^9$ or $–S(O)_2R^9$;

R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with C_{1-6} alkyl, halo, -CN, or $–C(O)OR^{9a}$, wherein R^{9a} is C_{1-6} alkyl; and


R^{11}, R^{12}, and R^{13} are each independently H, C_{1-6} alkyl, C_{1-6} haloalkyl, C_{1-6} heteroalkyl, C_{6-14} aryl, 5- to 10- membered heteroaryl, C_{3-8} cycloalkyl, or 3- to 10- membered heterocyclyl.

3. The compound of claim 1 or 2, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (II-a):




(II-a).

4. The compound of claim 1, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (III):




(III).

5. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (III-a):




(III-a).

6. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (III-b):



(III-b).

7. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein the compound is of formula (III-c):



(III-c).

8. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein

(a) ---- is a single bond; or

(b) ---- is a double bond; or

(c) L_1 is -CR'R''-; or

(d) L_1 is -O- or -NR'''-; or

(e) L_2 is a bond; or

(f) L_2 is -CH_2-.

~~9. The compound of claim 1 or 4, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein ==== is a double bond.~~

~~10. The compound of claim 1, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein L_1 is -CR'R''-.~~

~~11. The compound of claim 1, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein L_1 is -O- or -NR"'-.~~

~~12. The compound of claim 1, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein L_2 is a bond.~~

~~13. The compound of claim 1, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein L_2 is -CH_2-.~~

~~14~~9. The compound of any one of claims 1-6 and 8~~-13~~, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein

(a) R' is H; or

(b) R' is C_{1-6} alkyl, and optionally methyl; or

(c) (i) R" is H, or

(ii) R" is C_{1-6} alkyl, C_{1-6} haloalkyl, or halo.

~~15. The compound of any one of claims 1-6 and 8-13, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R' is C_{1-6} alkyl.~~

~~16. The compound of any one of claims 1-6 and 8-13, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R' is methyl.~~

~~17. The compound of any one of claims 1-6 and 8-13, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R" is H.~~

~~18. The compound of any one of claims 1-6 and 8-13, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R" is C_{1-6} alkyl, C_{1-6} haloalkyl, or halo.~~

~~19~~10. The compound of any one of claims 1-~~18~~9, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein

(a) R^2 is -OR^{13} and R^{13} is C_{1-6} alkyl, and optionally R^2 is -OCH_3 or -OCD_3; and/or

(b) R^3 is H; and/or

(c) R^4 is -OR^{13} and R^{13} is C_{1-6} alkyl, and optionally R^4 is -OCH_3 or -OCD_3; and/or

(d) (i) R^5 is H, or

(ii) R^5 is halo; and/or

(e) (i) R^1 is H, or

(ii) R^1 is halo.

~~20. The compound of any one of claims 1-18, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^2 is $-OCH_3$ or $-OCD_3$.~~

~~21. The compound of any one of claims 1-20, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^3 is H.~~

~~22. The compound of any one of claims 1-21, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^4 is $-OR^{13}$ and R^{13} is C_{1-6} alkyl.~~

~~23. The compound of any one of claims 1-21, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^4 is $-OCH_3$ or $-OCD_3$.~~


~~24. The compound of any one of claims 1-23, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^5 is H.~~

~~25. The compound of any one of claims 1-23, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^5 is halo.~~






~~26. The compound of any one of claims 1-25, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is H.~~

~~27. The compound of any one of claims 1-25, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 is halo.~~

~~28~~11. The compound of any one of claims ~~1-25~~1 or 8-9, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^1 and X are taken together with the carbons to which they are attached to form a 4- to 8- membered heterocyclyl.

~~29~~12. The compound of any one of claims 1-11~~28~~, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is a C_6 arylene, 5- to 6-membered heteroarylene, C_{5-6} cycloalkylene, or 5- to 6- membered heterocyclylene, and optionally A is 

.

~~30. The compound of any one of claims 1-29, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein A is~~  ~~,~~  ~~,~~  ~~,~~  ~~, or~~  ~~.~~

~~31~~13. The compound of any one of claims 1-~~30~~12, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein

(a) m is 0; or

(b) m is 1.

~~32. The compound of any one of claims 1-30, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein m is 1.~~

~~33~~14. The compound of any one of claims ~~1-30 and 32~~1-13, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein each R^7 is independently C_{1-6} alkyl or C_{1-6} haloalkyl, and optionally each R^7 is independently -CH_3, -CH_2CH_3, -$CH(CH_3)_2$, -CD_3, or –CH_2CF_3.

~~34. The compound of any one of claims 1-30 and 32, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein each R^7 is independently -CH_3, -CH_2CH_3, -$CH(CH_3)_2$, -CD_3, or -CH_2CF_3.~~




~~35~~15. The compound of any one of claims 1-~~34~~14, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein





(a) R^8 is –$C(O)R^9$; or

(b) R^8 is –$S(O)_2R^9$.


~~36. The compound of any one of claims 1-34, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^8 is -$S(O)_2R^9$.~~


~~37~~16. The compound of any one of claims 1-~~36~~15, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^9 is C_{1-6} alkyl, C_{2-6} alkenyl, or 3- to 10- membered heterocyclyl, each of which is optionally substituted with halo


or –C(O)OR^{9a}, wherein R^{9a} is C$_{1-6}$ alkyl, and optionally R^{9} is -CH$_3$, -CH$_2$CH$_3$, , , , or .


~~38. The compound of any one of claims 1-37, or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing, wherein R^{9} is -CH$_3$, -CH$_2$CH$_3$,~~ , , , , or .


~~39~~17. A compound selected from the ~~compounds in Table 1,~~ group consisting of


;


;

;


;

;


;


O
HN
HN–N
F
O
N–N
F
O
trans


;


O
HN
HN–N
Cl
O
N–N
Cl
O


;


O
HN
HN–N
F
D3C
O
N–N
F
O
D3C


;


O
HN
HN–N
F
O
N–N
D3C
F
O


;


O
HN
HN–N
F
O
N–N
F
O


;


O
HN
HN–N
F
O
N–N
CF3
F
O


;


O
HN
HN–N
F
O
N–N
H
O


;


O
HN
HN–N
F
O
N–NH
F
O


;


O
HN
HN–N
F
O
N–N
F
O


;


O
HN
HN–N
F
D3C
O
N–N
H
D3C
O


;


O
HN
HN–N
F
O
N–N
F
O


;


O
HN
HN–N
F
O
N–N
F
O


;


O
HN
HN–N
F
O
N–NH
F
O


;


O
HN
HN–N
F
O
N–N
F
O


;


O
HN
HN–N
F
O
N–N
D3C
O


;


O
HN
HN–N
F
O
N–NH
O


;


O
HN
HN
N
F
O
N
NH
O


;


O
HN
HN
N
F
O
N
N
O


;


O
O
F
H
N
O
N
H
N
N
N
O


;


O
F
O
F
H
N
N
HN
O
O


;


O
F
O
H
N
N
HN
O
O


;


O
F
O
F
H
N
N
HN
O
O


;


O
F
O
H
N
N
HN
O
O


;


O
F
O
F
H
N
N
HN
N
N
O


;


O
F
O
F
H
N
N
HN
N
N
O


;


O
F
O
H
N
N
HN
N
N
O


;


O
HN–N
HN
O
O
F
O
F
N–N
O


;


O
HN–N
HN
O
O
F
O
F
N–N
O


;


O
HN–N
HN
O
O
F
O
F
N–N
O


;


O
HN
HN–N
O
F
(R)
N–N
O
F


;


O
HN
HN–N
O
F
(S)
N–N
O
F


;


O
HN
HN–N
O
F
(R)
N–N
O
F


;


O
HN
HN–N
O
F
(S)
N–N
O
F


;


O
HN
HN–N
O
F
(R)
N–NH
O
F


;



;



; and



,

or a stereoisomer, tautomer, or a pharmaceutically acceptable salt of any of the foregoing.

~~40~~18. A pharmaceutical composition comprising at least one compound according to any one of claims 1-17~~39~~, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, and a pharmaceutically acceptable carrier or excipient.

19~~41~~. A kit comprising at least one compound according to any one of claims 1-17~~39~~, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing.

~~42~~20. ~~A method of treating a disease mediated by FGFR4 in an individual in need thereof, comprising administering to the individual a therapeutically effective amount~~ Use of a compound according to any one of claims 1-17~~39~~, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for treating a disease mediated by FGFR4.

~~43~~21. The use~~method~~ of claim 20~~42~~, wherein the compound is to be administered orally.

~~44~~22. The use~~method~~ of claim 20~~42~~, wherein the disease is cancer.

~~45~~23. ~~A method of inhibiting FGFR4, comprising contacting FGFR4 with~~Use of a compound according to any one of claims 1-17~~39~~, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing in the manufacture of a medicament for inhibiting FGFR4.

~~46~~24. ~~Use of a~~A compound of any one of claims 1-17~~39~~, or a stereoisomer, tautomer or a pharmaceutically acceptable salt of any of the foregoing, ~~in the manufacture of a medicament~~ for use in therapy.